HEART.ST Real Heart

Healthcare Health Care Equipment & Supplies Stockholm Exchange
16.70 SEK
Close of Nov 6, 2026
12.90 23.70
Market cap
SEK 142M
P/E
-
P/B
1.60x
ROE
-56.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is HEART.ST undervalued?

Graham number

The Graham number of Real Heart cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Real Heart fundamental analysis

No fundamental analysis for Real Heart yet.

Real Heart stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Real Heart

Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis for fixing the sternum after open-chest surgery. The company was founded in 1999 and is based in Västerås, Sweden.

Full company profile